Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Diabetes Ther
December 2024
Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Introduction: This analysis aimed to evaluate the long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg (both administered once weekly) in people not achieving glycemic control on metformin, based on the results of the head-to-head SURPASS J-mono trial from a Japanese healthcare payer perspective.
Methods: A cost-utility analysis was performed over a 50-year time horizon using an implementation of the UKPDS Outcomes Model 2 developed in Microsoft Excel.
Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia.
Cost Eff Resour Alloc
November 2024
Abbott Products Operations AG, BASEL-LAND, Nathan, 4123, Switzerland.
Background: This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications from diabetic neuropathy. Clinical evidence from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study demonstrated that fenofibrate can reduce the risk of amputation and other diabetes-related complications.
View Article and Find Full Text PDFUsing QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.
Med Decis Making
January 2025
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK.
Objectives: (1) To demonstrate the use of quality-adjusted life-years (QALYs) as an outcome measure for comparing performance between simulation models and identifying the most accurate model for economic evaluation and health technology assessment. QALYs relate directly to decision making and combine mortality and diverse clinical events into a single measure using evidence-based weights that reflect population preferences. (2) To explore the usefulness of Q, the proportional reduction in error, as a model performance metric and compare it with other metrics: mean squared error (MSE), mean absolute error, bias (mean residual), and .
View Article and Find Full Text PDFYounger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Lancet Diabetes Endocrinol
December 2024
Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Electronic address:
Background: Younger-onset type 2 diabetes is associated with accelerated complications. We assessed whether complications and mortality rates differed for younger age compared with older age at diagnosis over 30 years of follow-up.
Methods: In this study, we used data from the UKPDS, collected between 1977 and 2007, of participants aged 25-65 years with newly diagnosed type 2 diabetes with younger-onset (younger than 40 years) or later-onset (40 years or older), and without diabetes autoantibodies.
External validation and calibration of risk equations for prediction of diabetic kidney diseases among patients with type 2 diabetes in Taiwan.
Cardiovasc Diabetol
October 2024
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Article Synopsis
- Most current risk equations for predicting diabetic kidney disease (DKD) are based on outdated data from mostly Caucasian populations, prompting the need to adapt these models using real-world data from Taiwanese type 2 diabetes (T2D) patients.
- The study evaluated three simulation models (UKPDS-OM2, RECODe, and CHIME) for their ability to predict DKD progression, with results indicating that while some showed moderate discrimination, they often underestimated or overestimated risks.
- After recalibrating the equations, the updated RECODe for micro- and macroalbuminuria and the CHIME for renal failure exhibited improved predictions, making them suitable for use in a multi-state
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!